<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983914</url>
  </required_header>
  <id_info>
    <org_study_id>TES-NIS2021</org_study_id>
    <nct_id>NCT04983914</nct_id>
  </id_info>
  <brief_title>Retrospective NIS to Evaluate the Patient Benefit of TES</brief_title>
  <official_title>Retrospective Non-Interventional Study to Evaluate the Patient Benefit of Transcorneal Electrostimulation (TES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Okuvision GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CONET GmbH - Clinical Operations Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Okuvision GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this retrospective non-interventional study (NIS), the subjective and objective benefit of&#xD;
      patients with retinitis pigmentosa (and other dystrophies like Usher, Choroideremia or&#xD;
      cone-rod dystrophy), who have been prescribed the therapy of transcorneal electrostimulation&#xD;
      (TcES) with the OkuStim System, is assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The medical device OkuStim received the CE mark (a symbol of free marketability in the&#xD;
      European Economic Area) in 2011 and is commercially available for patients in Europe since&#xD;
      2014. Since then, patients with retinitis pigmentosa and other dystrophies have regularly&#xD;
      applied the therapy of transcorneal electrostimulation (TcES) with OkuStim. So far, the&#xD;
      benefits of the therapy and the experiences of the patients with regular, multi-year use have&#xD;
      not been systematically recorded.&#xD;
&#xD;
      In this retrospective non-interventional study (NIS) with patients which have been using TcES&#xD;
      since &gt;1 year, data present for visual field, best-corrected visual acuity (BCVA) and central&#xD;
      foveal thickness (as assessed via OCT) is collected. In addition, reasons for discontinuation&#xD;
      of therapy and patient satisfaction with TcES are assessed via a questionnaire. Side-effects&#xD;
      are also recorded, if present in the patient files.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual field</measure>
    <time_frame>Baseline and then all data present in patient files after begin of therapy. Depending on how long the patient already uses OkuStim, the time frame varies between 1 year and several years after commencement of therapy.</time_frame>
    <description>Assessment of changes compared to baseline (before TcES was started)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>Baseline and then all data present in patient files after begin of therapy. Depending on how long the patient already uses OkuStim, the time frame varies between 1 year and several years after commencement of therapy.</time_frame>
    <description>Assessment of changes compared to baseline (before TcES was started)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central foveal thickness</measure>
    <time_frame>Baseline and then all data present in patient files after begin of therapy. Depending on how long the patient already uses OkuStim, the time frame varies between 1 year and several years after commencement of therapy.</time_frame>
    <description>Assessment of changes compared to baseline (before TcES was started)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reasons for discontinuation of therapy and patient satisfaction</measure>
    <time_frame>Patients are asked to fill out the questionnaire once. Depending on how long the patient already uses OkuStim, the time frame varies between 1 year and several years after commencement of therapy</time_frame>
    <description>Custom-made questionnaire to assess reasons for discontinuation of therapy and patient satisfaction</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>All data present in patient files after begin of therapy. Depending on how long the patient already uses OkuStim, the time frame varies between 1 year and several years after commencement of therapy.</time_frame>
    <description>Adverse events will be recorded if present in the patient files. Only device-related adverse events will be analyzed</description>
  </other_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcorneal Electrostimulation via OkuStim System</intervention_name>
    <description>Transcorneal electrostimulation, usually applied once per week for 30 min (home-use).</description>
    <other_name>TcES</other_name>
    <other_name>TES</other_name>
    <other_name>OkuStim</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been prescribed the OkuStim System and who use the therapy for more than&#xD;
        one year are invited to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Use of TcES for &gt;1year&#xD;
&#xD;
          -  Willing and able to consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not willing and able to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Scholl, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University of Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katarina Stingl, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Eye Hospital Tuebingen, Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Schippert, PhD</last_name>
    <phone>+49 7121 15935</phone>
    <phone_ext>50</phone_ext>
    <email>ruth.schippert@okuvision.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alfred Stett, PhD</last_name>
    <phone>+49 7121 15935</phone>
    <phone_ext>11</phone_ext>
    <email>alfred.stett@okuvision.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Tübingen, Abt. für Augenheilkunde</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Kempf, M.Sc.</last_name>
      <email>melanie.kempf@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Saskia Ott, B.Sc.</last_name>
      <email>saskia.ott@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel, Augenklinik</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Hauenstein</last_name>
      <phone>+41 61 265 87 18</phone>
      <email>daniela.hauenstein@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Zabek O, Camenzind Zuche H, Müller U, Scholl HPN, Rickmann A, Della Volpe Waizel M. Optical coherence tomography angiography findings in patients undergoing transcorneal electrical stimulation for treating retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2021 May;259(5):1167-1177. doi: 10.1007/s00417-020-04963-7. Epub 2020 Oct 10.</citation>
    <PMID>33037922</PMID>
  </reference>
  <reference>
    <citation>Jolly JK, Wagner SK, Martus P, MacLaren RE, Wilhelm B, Webster AR, Downes SM, Charbel Issa P, Kellner U, Jägle H, Rüther K, Bertelsen M, Bragadóttir R, Prener Holtan J, van den Born LI, Sodi A, Virgili G, Gosheva M, Pach J, Zündorf I, Zrenner E, Gekeler F. Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa: A Multicenter Safety Study of the OkuStim® System (TESOLA-Study). Ophthalmic Res. 2020;63(3):234-243. doi: 10.1159/000505001. Epub 2019 Nov 26.</citation>
    <PMID>31775146</PMID>
  </reference>
  <reference>
    <citation>Schatz A, Pach J, Gosheva M, Naycheva L, Willmann G, Wilhelm B, Peters T, Bartz-Schmidt KU, Zrenner E, Messias A, Gekeler F. Transcorneal Electrical Stimulation for Patients With Retinitis Pigmentosa: A Prospective, Randomized, Sham-Controlled Follow-up Study Over 1 Year. Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):257-269. doi: 10.1167/iovs.16-19906.</citation>
    <PMID>28114587</PMID>
  </reference>
  <reference>
    <citation>Schatz A, Röck T, Naycheva L, Willmann G, Wilhelm B, Peters T, Bartz-Schmidt KU, Zrenner E, Messias A, Gekeler F. Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study. Invest Ophthalmol Vis Sci. 2011 Jun 23;52(7):4485-96. doi: 10.1167/iovs.10-6932.</citation>
    <PMID>21467183</PMID>
  </reference>
  <reference>
    <citation>Sinim Kahraman N, Oner A. Effect of Transcorneal Electrical Stimulation on Patients with Retinitis Pigmentosa. J Ocul Pharmacol Ther. 2020 Oct;36(8):609-617. doi: 10.1089/jop.2020.0017. Epub 2020 May 19.</citation>
    <PMID>32429728</PMID>
  </reference>
  <reference>
    <citation>Della Volpe-Waizel M, Zuche HC, Müller U, Rickmann A, Scholl HPN, Todorova MG. Metabolic monitoring of transcorneal electrical stimulation in retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2020 Jan;258(1):79-87. doi: 10.1007/s00417-019-04522-9. Epub 2019 Nov 12.</citation>
    <PMID>31713752</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcorneal Electrostimulation</keyword>
  <keyword>TcES</keyword>
  <keyword>TES</keyword>
  <keyword>Inherited retinal dystrophy</keyword>
  <keyword>Retinopathia pigmentosa</keyword>
  <keyword>Retinitis pigmentosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

